Elisabet Sicart

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

Jordi Rodón, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez et al. · Clinical Cancer Research · 2014 · 232 citations

Medicine, Oncology, Pharmacology +13

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Jordi Rodón, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez et al. · Investigational New Drugs · 2014 · 105 citations · Full text

Medicine, Oncology, Pharmacology +17

First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.

José Baselga, E. Calvo, Joan Seoane et al. · Journal of Clinical Oncology · 2011 · 30 citations

Medicine, Oncology, Pharmacology +17

Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor, LY2157299 monohydrate (LY).

Jordi Rodón, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez et al. · Journal of Clinical Oncology · 2013 · 13 citations

Medicine, Oncology, Pharmacology +17